Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
D000328:Adult; D000368:Aged; D001479:Basal Ganglia / Q000378:metabolism; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001923:Brain Chemistry / Q000187:drug effects; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D009055:Mouth / Q000503:physiopathology; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D013747:Tetrabenazine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use
D010919:Placebos; D014149:Tranquilizing Agents; D004298:Dopamine; D013747:Tetrabenazine